Products eligible for the medical use format under the EPC: new insights, Managing IP 2024

In the latest article published by Managing IP, Dr. Eva Ehlich and Dr. Anja Fux summarise an EPO board ruling relating to substances and compositions in the context of medical use claims and how it could affect applicants’ portfolio strategies